Investigational new drugs for the treatment of Dravet syndrome: an update

References

• Dravet C. Les épilepsies graves de l’enfant. Vie Med. 1978;8:543–548.
   Google Scholar
• Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(s2):1–6.
   PubMedGoogle Scholar
• Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3–9.
   PubMedGoogle Scholar
• Chilcott E, Díaz JA, Bertram C, et al. Genetic therapeutic advancements for Dravet syndrome. Epilepsy Behav. 2022;132:108741.
   PubMedGoogle Scholar
• Strzelczyk A, Schubert-Bast S, Practical A. Guide to the treatment of Dravet syndrome with anti-seizure medication. CNS Drugs. 2022;36(3):217–237.
   PubMedGoogle Scholar
• Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761–1777.
   PubMed Web of Science ®Google Scholar
• Riva A, D’Onofrio G, Amadori E, et al. Current and promising therapeutic options for Dravet syndrome. Expert Opin Pharmacother. 2022;23(15):1727–1736.
   PubMed Web of Science ®Google Scholar
• Lopez JC, Pare JR, Blackmer AB, et al. Treatment-refractory Dravet syndrome: considerations for novel medications. J Pediatr Health Care. 2022;36(5):479–488.
   PubMedGoogle Scholar
• Valassina N, Brusco S, Salamone A, et al. Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome. Nat Commun. 2022;13(1):161.
   PubMedGoogle Scholar
• Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol. 2009;16(2):107–113.
   PubMed Web of Science ®Google Scholar
• Wengert ER, Wagley PK, Strohm SM, et al. Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome. Brain Res. 2022;1775:147743.
   PubMed Web of Science ®Google Scholar
• Han Z, Chen C, Christiansen A, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020;12(558):eaaz6100.
   PubMed Web of Science ®Google Scholar
• Clinical Studies [Internet]. Stoke therapeutics. [ Cited 2023 Jan 28]. Available from: https://www.stoketherapeutics.com/pipeline/studies/
   Google Scholar
• Stoke Therapeutics, Inc. An open-label study to investigate the safety and pharmacokinetics of single and multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome [Internet]. clinicaltrials.gov; 2022 Feb [cited 2023 Jan 24]. Report No.: NCT04442295. Available from: https://clinicaltrials.gov/ct2/show/NCT04442295
   Google Scholar
• Stoke therapeutics presents data from a combined interim analysis of the phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in children and adolescents with Dravet syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting - Stoke Therapeutics [Internet]. [Cited 2023 Jan 28]. Available from: https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-presents-data-combined-interim-analysis-phase/
   Google Scholar
• Hsiao J, Yuan TY, Tsai MS, et al. Upregulation of haploinsufficient gene expression in the brain by targeting a long non-coding RNA improves seizure phenotype in a model of Dravet syndrome. EBioMedicine. 2016;9:257–277.
   PubMed Web of Science ®Google Scholar
• Ünalp A, Coskunpinar E, Gunduz K, et al. Detection of deregulated miRNAs in childhood epileptic encephalopathies. J Mol Neurosci. 2022;72(6):1234–1242.
   PubMedGoogle Scholar
• Gerbatin RR, Augusto J, Morris G, et al. Investigation of MicroRNA-134 as a target against seizures and SUDEP in a mouse model of Dravet syndrome. eNeuro. 2022;9(5):ENEURO.0112–22.2022.
   PubMedGoogle Scholar
• Giagtzoglou N. SCN1A-Upregulation-by-an-Antisense-Oligonucleotide-Targeting-SCN1ANAT-for-Treatment-of-Dravet-Syndrome. American Epilepsy Society Annual Meeting, Nashville, TN, December 2–6, 2022. [Internet]. AES. [Cited 2023 Jan 28]. Available from: https://cms.aesnet.org/abstractslisting/scn1a-upregulation-by-an-antisense-oligonucleotide-targeting-scn1anat-for-treatment-of-dravet-syndrome
   Google Scholar
• Porter JJ, Heil CS, Lueck JD. Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip Rev RNA. 2021;12(4):e1641.
   PubMedGoogle Scholar
• Dracaena_DravetSyndromePipelineReview_2022.pdf [Internet]. [Cited 2023 Jan 28]. Available from: https://static1.squarespace.com/static/54589576e4b01c74d3bdbdd3/t/639b0e7b09a8286ea8f9ca61/1671106183307/Dracaena_DravetSyndromePipelineReview_2022.pdf
   Google Scholar
• Tanenhaus A, Stowe T, Young A, et al. Cell-Selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates. Hum Gene Ther. 2022;33(11–12):579–597.
   PubMed Web of Science ®Google Scholar
• Encoded therapeutics. ENDEAVOR: a clinical study to evaluate the safety and efficacy of ETX101, an AAV9-delivered gene therapy in infants and children With SCN1A-positive Dravet syndrome [Internet]. clinicaltrials.gov; 2022 Jun [Cited 2023 Jan 26]. Report No.: NCT05419492. Available from: https://clinicaltrials.gov/ct2/show/NCT05419492
   Google Scholar
• Mora-Jimenez L, Valencia M, Sanchez-Carpintero R, et al. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations. Mol Ther Nucleic Acids. 2021;25:585–602.
   PubMedGoogle Scholar
• Goodchild SJ, Burford K, Dube C, et al. Molecularly Selective NaV1.1 potentiators increase PV+ fast-spiking interneuron excitability and restore motor performance in a mouse model of Dravet syndrome. Poster No. 3.049, American Epilepsy Society Annual Meeting, Nashville, TN, December 2–6, 2022.
   Google Scholar
• DIACOMIT_US_PI_2022.pdf [Internet]. [ Cited 2023 Jan 28]. Available from: https://www.diacomit.com/wp-content/uploads/2022/10/DIACOMIT_US_PI_2022.pdf
   Google Scholar
• Wu J, Zhang L, Zhou X, et al. Efficacy and safety of adjunctive antiseizure medications for Dravet syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:980937.
   PubMedGoogle Scholar
• Talwar A, Estes E, Aparasu R, et al. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. Exp Neurol. 2023;359:114238.
   PubMedGoogle Scholar
• Jensen MP, Gammaitoni AR, Galer BS, et al. Fenfluramine treatment for Dravet syndrome: real-world benefits on quality of life from the caregiver perspective. Epilepsy Res. 2022;185:106976.
   PubMedGoogle Scholar
• Jensen MP, Gammaitoni AR, Salem R, et al. Fenfluramine treatment for Dravet syndrome: caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom. Epilepsy Res. 2023;190:107091.
   PubMedGoogle Scholar
• Agarwal A, Farfel GM, Gammaitoni AR, et al. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2022;39:35–39.
   PubMedGoogle Scholar
• Guerrini R, Specchio N, Á A-S, et al. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the Fenfluramine European Early Access Program. Epilepsia Open. 2022;7(4):578–587.
   Google Scholar
• Bishop KI, Isquith PK, Gioia GA, et al. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: a critical period for early neurodevelopment. Epilepsy Behav. 2023;138:108994.
   PubMedGoogle Scholar
• Hahn CD, Jiang Y, Villanueva V, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022;63(10):2671–2683.
   PubMedGoogle Scholar
• A study of soticlestat as an add-on therapy in children and young adults with Dravet syndrome - tabular view - clinicalTrials.gov [Internet]. [ Cited 2023 Jan 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04940624
   Google Scholar
• Moog M, Baraban SC. Clemizole and trazodone are effective antiseizure treatments in a zebrafish model of STXBP1 disorder. Epilepsia Open. 2022;7(3):504–511.
   PubMedGoogle Scholar
• Longboard Pharmaceuticals. Randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, PK, PD, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies [Internet]. clinicaltrials.gov; 2023 Jan [Cited 2023 Jan 26]. Report No.: NCT05364021. Available from: https://clinicaltrials.gov/ct2/show/NCT05364021
   Google Scholar
• Parasrampuria D, Mills I, O‘Connell G, et al. Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14–8.001). Neurology. Internet. 2022;98(18Supplement):1750.
   Google Scholar
• Sourbron J, Lagae L. Serotonin receptors in epilepsy: novel treatment targets? Epilepsia Open. 2022;7(2):231–246.
   PubMedGoogle Scholar
• Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627–633.
   PubMedGoogle Scholar
• Steel D, Symonds JD, Zuberi SM, et al. Dravet syndrome and its mimics: beyond SCN1A. Epilepsia. 2017;58(11):1807–1816.
   PubMed Web of Science ®Google Scholar
• Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015;43(1):78–89.
   PubMed Web of Science ®Google Scholar
• High KA, Roncarolo MG. Gene Therapy. N Engl J Med. 2019;381(5):455–464.
   PubMed Web of Science ®Google Scholar